KRYS stock news · Krystal Biotech, Inc.
Get alerts for KRYS
Follow Krystal Biotech, Inc. (KRYS) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for KRYSFree on the App Store and Google Play, or on the web.
Krystal Biotech shared its financial results for the quarter that ended on September 30, 2026.
NeutralKrystal Biotech filed a report announcing results for the quarter ended September 30, 2026, but this text gives no result figures. It does not show a change in the company's business outlook.
Krystal Biotech says its skin cancer treatment cut tumors by more than 80% in a trial.
Good for KRYSKrystal Biotech reported tumor shrinkage in a small skin cancer study. The early results support its outlook, though larger studies and FDA plans remain ahead.
Krystal Biotech says its skin cancer treatment cut lesions by more than 80% in a rare disease trial.
Good for KRYSKrystal Biotech's early KB113 study found broad tumor shrinkage and manageable side effects in 3 people. The results support more testing, though the study is small.